Welcome to our dedicated page for Know Labs news (Ticker: KNW), a resource for investors and traders seeking the latest updates and insights on Know Labs stock.
Know Labs Inc (KNW) pioneers non-invasive diagnostic technologies using its patented Bio-RFID and ChromaID systems, transforming traditional medical testing methods. This page serves as the definitive source for verified updates on the company's regulatory progress, clinical validations, and strategic partnerships in the healthtech sector.
Access real-time announcements about wearable device developments, FDA submissions, and peer-reviewed study results. Investors and healthcare professionals will find curated updates on product commercialization timelines, intellectual property expansions, and collaborative research initiatives.
Key content includes earnings call summaries, technology licensing agreements, and analysis of clinical trial outcomes. All materials adhere to journalistic standards for accuracy, providing actionable insights without speculative commentary.
Bookmark this page to monitor Know Labs' advancements in replacing invasive blood tests with electromagnetic-based solutions, including their flagship non-invasive glucose monitor currently under regulatory review.
Know Labs, Inc. (KNW) has announced successful results from a proof-of-principle study demonstrating the accuracy of its proprietary Bio-RFID technology in non-invasive medical diagnostics. Conducted in collaboration with Mayo Clinic, the study, titled "Detecting Unique Analyte-Specific Radio Frequency Spectral Responses in Liquid Solutions," showcased a remarkable 100% accuracy rate in measuring various analytes in vitro. This breakthrough technology captures molecular signatures using radio waves, with glucose monitoring being its first application. Market trends highlighting the need for affordable, accurate non-invasive healthcare solutions further bolster the significance of these results. The full study awaits peer-review publication.
Know Labs, Inc. (NYSE American: KNW) has formed a new Scientific Advisory Board (SAB) featuring leading experts in medical technology and human health. This board aims to enhance Know Labs' efforts in algorithm refinement, device development, and clinical trial design for its Bio-RFID technology, which aims to offer non-invasive glucose monitoring. The SAB includes esteemed members like Dr. Benjamin Smarr and Dr. Mark Aloia, who bring extensive backgrounds in research and technology. Know Labs emphasizes 2023 as a year of prioritizing external validation of its non-invasive diagnostic technology.
FAQ
What is the current stock price of Know Labs (KNW)?
What is the market cap of Know Labs (KNW)?
